Romiplostim as a Therapeutic Intervention for Tacrolimus-induced Immune Thrombocytopenia in a Pediatric Cardiac Transplant Patient. Issue 6 (August 2021)

• Record Type: Journal Article
• Authors: Gipson, Daniel R.; Larkin, Trisha; Seifert, Robert; Black, L. Vandy
• Is Part Of: Journal of pediatric hematology/oncology. Volume 43:Issue 6(2021)
• Publication Date: 2021-08
• Subjects: immune thrombocytopenia -- tacrolimus -- romiplostim -- pediatric -- transplant; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; 618.9215
• DOI: 10.1097/MPH.0000000000001994
• Languages: English
• ISSNs: 1077-4114

Abstract

Abstract : Tacrolimus-induced immune thrombocytopenia (ITP) is a rare entity that can occur years after initiation of tacrolimus therapy following solid organ transplantation, and platelet recovery can be substantially delayed following discontinuation of tacrolimus. Romiplostim, a thrombopoietin receptor agonist approved by the FDA in 2018 for the treatment of chronic ITP in children, may be a useful therapy to hasten platelet recovery in the acute ITP setting in place of immunomodulating agents. We present a case of tacrolimus-induced ITP successfully treated with romiplostim in a child following cardiac transplantation.